ERBB2 and breast carcinoma: For example, the HER2D16 splicing variant is highly expressed in a subset of HER2+ breast cancer patients with resistance to trastuzumab, a HER2-targeted therapy (Palladini et al., 2017; Hsu et al., 2020).